NR3C2 and heart failure: In our HFC, ACEIs, ARBs, aldosterone receptor antagonists, evidence-based β-blockers, and ARNIs are the most commonly prescribed drugs that are newly added or given in an increased dose at the registry based on clinical judgment for the management of heart failure.